Cargando…

Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties

Inhibition of PDE5 results in elevation of cGMP leading to vascular relaxation and reduction in the systemic blood pressure. Therefore, PDE5 inhibitors are used as antihypertensive and antianginal agents in addition to their major use as male erectile dysfunction treatments. Previously, we developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	Amin, Kamelia M., El-Badry, Ossama M., Abdel Rahman, Doaa E., Abdellattif, Magda H., Abourehab, Mohammed A. S., El-Maghrabey, Mahmoud H., Elsaid, Fahmy G., El Hamd, Mohamed A., Elkamhawy, Ahmed, Ammar, Usama M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501832/ https://www.ncbi.nlm.nih.gov/pubmed/36145702 http://dx.doi.org/10.3390/pharmaceutics14091954

Ejemplares similares

Determination of Phosphodiesterase Type-5 Inhibitors (PDE-5) in Dietary Supplements
por: Gheorghiu, Oana Ramona Cătălina, et al.
Publicado: (2023)

Acute effects of phosphodiesterase 5 (PDE5) inhibition, ANP and NO on epididymal contractility are preserved despite chronic PDE5 exposure
por: Mietens, Andrea, et al.
Publicado: (2011)

Development of New Meridianin/Leucettine-Derived Hybrid Small Molecules as Nanomolar Multi-Kinase Inhibitors with Antitumor Activity
por: Elsherbeny, Mohamed H., et al.
Publicado: (2021)

Scaffold Repurposing of In-House Small Molecule Candidates Leads to Discovery of First-in-Class CDK-1/HER-2 Dual Inhibitors: In Vitro and In Silico Screening
por: Elkamhawy, Ahmed, et al.
Publicado: (2021)

Identification of cytosolic phosphodiesterases in the erythrocyte: A possible role for PDE5
por: Adderley, Shaquria P., et al.
Publicado: (2011)

Type 5 phosphodiesterase (PDE5) and the vascular tree: From embryogenesis to aging and disease
por: Cesarini, Valeriana, et al.
Publicado: (2020)

Calcium/Calpain mediated regulation of cyclic nucleotide phosphodiesterases, PDE3A and PDE5, in human platelets
por: Rybalkina, Irina G, et al.
Publicado: (2011)

Meta-Analysis of the Association Between Phosphodiesterase Inhibitors (PDE5Is) and Risk of Melanoma
por: Loeb, Stacy, et al.
Publicado: (2017)

Reversal of neurobehavioral social deficits in dystrophic mice using inhibitors of phosphodiesterases PDE5A and PDE9A
por: Alexander, M S, et al.
Publicado: (2016)

4-Anilinoquinazoline-based benzenesulfonamides as nanomolar inhibitors of carbonic anhydrase isoforms I, II, IX, and XII: design, synthesis, in-vitro, and in-silico biological studies
por: Nada, Hossam, et al.
Publicado: (2022)

Development of a New Radiofluorinated Quinoline Analog for PET Imaging of Phosphodiesterase 5 (PDE5) in Brain
por: Liu, Jianrong, et al.
Publicado: (2016)

Phosphodiesterase 5 (PDE5) Is Highly Expressed in Cancer-Associated Fibroblasts and Enhances Breast Tumor Progression
por: Catalano, Stefania, et al.
Publicado: (2019)

On the Viability of Tadalafil-Based (18)F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging
por: Bailey, Justin J., et al.
Publicado: (2021)

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity
por: Santos, Jaime, et al.
Publicado: (2021)

Design, synthesis and biological evaluation of new 2-aminothiazole scaffolds as phosphodiesterase type 5 regulators and COX-1/COX-2 inhibitors
por: Hussein, Abdel Haleem M., et al.
Publicado: (2020)

Phosphodiesterase 5 (PDE5) restricts intracellular cGMP accumulation during enterotoxigenic Escherichia coli infection
por: Foulke-Abel, Jennifer, et al.
Publicado: (2020)

Phosphodiesterase 5 (PDE-5) inhibitors (sildenafil, tadalafil, and vardenafil) effects on esophageal motility: a systematic review
por: Shafiee, Arman, et al.
Publicado: (2023)

Impact of phosphodiesterases PDE3 and PDE4 on 5-hydroxytryptamine receptor4-mediated increase of cAMP in human atrial fibrillation
por: Dolce, Bernardo, et al.
Publicado: (2020)

Phosphodiesterase Type 5 (PDE5) Inhibitors Sensitize Topoisomerase II Inhibitors in Killing Prostate Cancer Through PDE5-Independent Impairment of HR and NHEJ DNA Repair Systems
por: Chang, Jo-Fan, et al.
Publicado: (2019)

Effect of phosphodiesterase-5 inhibitors (PDE5is) on the treatment of male infertility: A protocol for systematic review and meta-analysis
por: Dong, Liang, et al.
Publicado: (2019)

Rapid Screening and Quantitative Determination of Illegal Phosphodiesterase Type 5 Inhibitors (PDE-5i) in Herbal Dietary Supplements
por: Nguyen, Thi Oanh, et al.
Publicado: (2021)

2-(3-Bromophenyl)-8-fluoroquinazoline-4-carboxylic Acid as a Novel and Selective Aurora A Kinase Inhibitory Lead with Apoptosis Properties: Design, Synthesis, In Vitro and In Silico Biological Evaluation
por: Elsherbeny, Mohamed H., et al.
Publicado: (2022)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Effect of a phosphodiesterase-5A (PDE5A) gene polymorphism on response to sildenafil therapy in canine pulmonary hypertension
por: Ueda, Yu, et al.
Publicado: (2019)

Luteinizing Hormone Causes Phosphorylation and Activation of the cGMP Phosphodiesterase PDE5 in Rat Ovarian Follicles, Contributing, Together with PDE1 Activity, to the Resumption of Meiosis
por: Egbert, Jeremy R., et al.
Publicado: (2016)

Advancements in Phosphodiesterase 5 Inhibitors: Unveiling Present and Future Perspectives
por: ElHady, Ahmed K., et al.
Publicado: (2023)

Effect of Phosphodiesterase-5 (PDE-5) Inhibitors on Clinical Outcomes in Patients With Pulmonary Hypertension: A Meta-Analysis of Randomized Control Trials
por: Karedath, Jithin, et al.
Publicado: (2023)

Expression of Phosphodiesterase (PDE) Isoenzymes in the Human Male and Female Urethra
por: Rahardjo, Harrina E, et al.
Publicado: (2021)

Effects of the Phosphodiesterase-5 (PDE-5) Inhibitors, Avanafil and Zaprinast, on Bone Remodeling and Oxidative Damage in a Rat Model of Glucocorticoid-Induced Osteoporosis
por: Huyut, Zübeyir, et al.
Publicado: (2018)

Expression of phosphodiesterase 6 (PDE6) in human breast cancer cells
por: Dong, Hongli, et al.
Publicado: (2013)

Inhaled Phosphodiesterase 4 (PDE4) Inhibitors for Inflammatory Respiratory Diseases
por: Phillips, Jonathan E.
Publicado: (2020)

Treatment of Experimental Autoimmune Encephalomyelitis with an Inhibitor of Phosphodiesterase-8 (PDE8)
por: Basole, Chaitali P., et al.
Publicado: (2022)

Role of Phosphodiesterase 7 (PDE7) in T Cell Activity. Effects of Selective PDE7 Inhibitors and Dual PDE4/7 Inhibitors on T Cell Functions
por: Szczypka, Marianna
Publicado: (2020)

3-nitroimidazo[1,2-b]pyridazine as a novel scaffold for antiparasitics with sub-nanomolar anti-Giardia lamblia activity
por: Zheng, Yang, et al.
Publicado: (2022)

Nanomolar-Potency Small Molecule Inhibitor of STAT5 Protein
por: Cumaraswamy, Abbarna A., et al.
Publicado: (2014)

Safety and Efficacy of Ambrisentan–Phosphodiesterase Type 5 (PDE5) Inhibitor Combination Therapy for Japanese Pulmonary Arterial Hypertension Patients in Real-World Clinical Practice
por: Kataoka, Masaharu, et al.
Publicado: (2019)

Phosphodiesterase type 5 inhibitors: Irrational use in Saudi Arabia
por: Alshahrani, Saad, et al.
Publicado: (2016)

Phosphodiesterase 9 (PDE9) regulates bovine tracheal smooth muscle relaxation
por: TAJIMA, Tsuyoshi, et al.
Publicado: (2018)

Inhibition of calcium-calmodulin-dependent phosphodiesterase (PDE1) suppresses inflammatory responses
por: O'Brien, Jennifer J., et al.
Publicado: (2019)

Type-4 Phosphodiesterase (PDE4) Blockade Reduces NETosis in Cystic Fibrosis
por: Totani, Licia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_npr62jfacujjt7la3snobgkq41